NY-KYNDRYL
Kyndryl (NYSE: KD), the world's largest IT infrastructure services provider, today announced a new open integration platform giving business leaders real-time insights into their complex IT estates, and unprecedented control over customizing their mission-critical operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005855/en/
Kyndryl Introduces New Platform, Kyndryl Bridge, to Orchestrate IT Estates and Drive Business Growth (Graphic: Business Wire)
Kyndryl Bridge leverages Kyndryl’s core technology strengths. It marshals decades of expertise, operational data patterns and IP to generate actionable insights that redefine how enterprises improve and accelerate their AI-powered analytics and business objectives. In doing so, it creates an uninterrupted path between digital business and the tech that drives it. Kyndryl Bridge is designed to meet customers where they are today, enabling interoperability that maximizes the value of tools they already know and trust.
“Dealing with complexity is what Kyndryl does best, and what customers need most. Kyndryl Bridge will be a way for our customers, and Kyndryl, to run their mission-critical infrastructure and digital transformation journeys better,” said Martin Schroeter, Kyndryl’s Chairman and Chief Executive Officer. “Kyndryl is committed to transforming how IT services are delivered, and Kyndryl Bridge is core to our long-term strategic mission to grow our ecosystem of alliance partners, use tools and IP to create a robust advanced delivery system, and ultimately dedicate more expertise and focus to best serve customers at scale.”
Across the global economy, digital modernization efforts sit at the top of today’s business agendas, with 60 percent of CIOs citing it as their most critical growth driver in 2022. However, business and technology complexity — along with a shortage of critical IT skills — has slowed progress for most enterprises. Kyndryl is accelerating its customers’ digital business journeys by innovating to deliver solutions through platform-enabled services.
“Enterprise IT leaders today are responsible for the management of increasingly-complex IT estates that demand greater oversight, interoperability, and AI-powered analytics to avert challenges and downtime,” says David Tapper, program VP, Outsourcing and Managed Cloud Service at IDC. “The ability of Kyndryl Bridge to connect the many tools, workflows, and processes in which enterprises have spent years investing, while delivering real-time, actionable insights and recommendations, is a powerful proposition for enterprises throughout the global economy.”
Kyndryl Bridge integrates and connects the complex management and process tools that enterprises throughout the global economy rely upon. Its capabilities have, on average, reduced the number of incidents per server per month for enterprises by 74 percent.
“By enabling leaders to focus less on managing IT systems, they can build and support their digital business strategies while freeing up IT resources for higher-value work,” said Antoine Shagoury, Kyndryl’s Chief Technology Officer. “It provides greater access and control over critical tools, and Kyndryl experts in cloud, data and AI, security and resiliency, mainframe modernization, and other important aspects of the IT estate.”
Designed with configurability in mind, Kyndryl Bridge is evolving to deploy ready-made, industrial scale solutions from Kyndryl and its broad and growing partner ecosystem. Its intelligent management tools, powered by automation and AI, will provide technology leaders with real-time insights to prevent downtime and better forecast future needs and costs.
“As customers accelerate their digital transformation, Kyndryl’s new digital integration platform can help provide rich data insights, solutions automation, and services delivery expertise,” said Nick Holden, Vice President, Cisco Global Strategic Partners and Co-sell. “Kyndryl Bridge is a big step forward to enable Kyndryl and Cisco to deliver business outcomes that our joint customers are demanding.”
For customers, the platform maximizes the benefits of native multi-cloud capabilities and delivers an ‘as-a-service’ (aaS) operating environment. It is designed to be a strategic digital hub, that will continue to expand and grow over time, connecting Kyndryl’s advanced technology and tooling with a deep bench of industry expertise and forward-thinking innovators across virtually every sector of the global economy.
About Kyndryl
Kyndryl (NYSE: KD) is the world’s largest IT infrastructure services provider serving thousands of enterprise customers in more than 60 countries. The Company designs, builds, manages, and modernizes the complex, mission-critical information systems that the world depends on every day. For more information, visit www.kyndryl.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
